What does General Biologicals Corporation do?

General Biologicals Corporation (4117.TWO) operates in the Medical - Specialties industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 4117.TWO's market cap?

General Biologicals Corporation (4117.TWO) has a market capitalization of approximately $650.5 million, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 4117.TWO pay a dividend?

No — General Biologicals Corporation (4117.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 4117.TWO profitable?

General Biologicals Corporation (4117.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

4117.TWO

General Biologicals Corporation

TWO·Medical, Specialties · Healthcare

NT$9.25NT$0.02−0.22%

Market capNT$650.50M·Aug 26 6:59 AM UTC

Price Chart

NT$9.25−NT$0.02 (−0.22%)today

−75.66%CAGR −24.62%

Select date range

FromTo

Oct 25, 2007Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

4117.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateFeb 26

Last Report DateJun 30

Reported vs Estimate−NT$2.15

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$260.23M

Net IncomeNT$518.98M

Net Margin199.4%

Operating Cash Flow−NT$77.27M

Capital ExpendituresNT$5.27M

Free Cash Flow−NT$82.54M

Return on Equity65.2%

Return on Invested Capital−1.4%

Net DebtNT$1.92B

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 4117.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 4117.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 4117.TWO and 80,000+ other tickers.

About General Biologicals Corporation

General Biologicals Corporation (GBC) is a company dedicated to the research, development, production, and global commercialization of in-vitro diagnostic (IVD) solutions, operating extensively both within Taiwan and internationally. The company's core diagnostic offerings include advanced ELISA and chemiluminescence immunoassays, molecular and cellular diagnostic platforms, and rapid point-of-care testing (POCT) systems. Its diverse portfolio further encompasses COVID-19 related solutions, digital pathology, and contract development manufacturing organization (CDMO) services. Additionally…

CEO: Frank Lin
Sector: Healthcare
Industry: Medical - Specialties
Exchange: TWO
Employees: 200
Website: www.gbc.com.tw

Peers

Peers Tab

3373.TWO

Radiant Innovation Inc.

Cap

NT$790.5M

4198.TWO

S&S Healthcare Holding Ltd.

Cap

NT$993.2M

6917.TWO

Andros Pharmaceuticals Co.,Ltd

Cap

NT$1.8B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 4117.TWO

What does General Biologicals Corporation do?: General Biologicals Corporation (4117.TWO) operates in the Medical - Specialties industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 4117.TWO's market cap?: General Biologicals Corporation (4117.TWO) has a market capitalization of approximately $650.5 million, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 4117.TWO pay a dividend?: No — General Biologicals Corporation (4117.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 4117.TWO profitable?: General Biologicals Corporation (4117.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.